Interview with management about events during Q2
Interview with CEO Anna Eriksrud and CFO Aaron Wong about events during Q2 and The Why, The What and The When for rights issue starting today.
CEO Anna Eriksrud gave a short introduction to the company and the strategy. Further updating the investor community on the PULSE study and the feedback on the data so far. The data was presented at the SBI Breast Imaging Symposium in Maryland USA. The data demonstrated a 93% success rate of biopsies from the lymph node.
CFO Aaron Wong presented the figures for Q2 and no material revenue so far. But re-introduction of Core-Pulse needles after fine-tuning is ongoing in the UK and DACH region. The company expects sales to materialize in the second half of 2023, when commercial efforts in US solidify. Costs both external and personnel increased due to establishment of NeoDynamics Inc. Both CEO Anna Eriksrud and CFO Aaron Wong are confident about commercial breakthrough in the US.
To secure long-term financing the Company carry out and rights issue of SEK 72 mio. in shares and warrants with preferential rights for existing shareholders. The net proceeds are used for full commercialization and marketing activities in the US and Europe. The rights issue starts the 2nd. of August and runs until the 16th. of August both days included.
Listen to interview here: Interview with management
Read the prospectus here: Prospectus
How to subscribe for new shares here(by clicking the link - you enter Redeye's landing page):Subscribe for new shares
Disclaimer:
HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:20 AM 02-08-2023.
